Trials investigating the effect of drugs specifically targeting BRAFV600E mutants, such as vemurafenib, given as monotherapy, have failed in mut-BRAF colorectal cancers [140], even though they proved to be effective in melanomas harboring the same mutation [141]. Here, BRAF is linked to melanoma.